Fulvestrant Injection
Product Images NDC 62332-650

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 62332-650). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fulvestrant-carton-label (Fulvestrant Carton Label)

Packaging label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) by Alembic Pharmaceuticals Inc. The carton contains two single-dose prefilled syringes for intramuscular use, totaling 500 mg of fulvestrant. Storage instructions indicate refrigeration at 2° to 8°C, protection from light, and storage in the original carton until use. The label includes dosage warnings, administration instructions, and barcoding for identification.*

FDA Label Image

Fulvestrant-fig-1 (Fulvestrant Fig 1)

An instructional illustration showing the steps for preparing an injection. It includes a hand holding a vial upside down with a syringe being inserted, a crossed-out symbol indicating incorrect practice, and labeled components of a vial and syringe used for intramuscular injection preparation.*

FDA Label Image

Fulvestrant-fig-10 (Fulvestrant Fig 10)

A Kaplan-Meier survival curve showing overall survival probability (%) over time in months for patients treated with Fulvestrant plus palbociclib and Fulvestrant plus placebo. The graph includes patient counts at risk at various time points up to 54 months, comparing survival outcomes between the two treatment groups.*

FDA Label Image

Fulvestrant-fig-11 (Fulvestrant Fig 11)

A Kaplan-Meier survival curve showing progression-free survival probability (%) over time (months) comparing Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo. The solid line represents 446 patients receiving Fulvestrant plus Abemaciclib, and the dashed line represents 223 patients receiving Fulvestrant plus Placebo. Number of patients at risk over time is listed below the graph.*

FDA Label Image

Fulvestrant-fig-12 (Fulvestrant Fig 12)

A Kaplan-Meier survival probability curve compares patients treated with Fulvestrant plus Abemaciclib versus Fulvestrant plus Placebo over time in months. The y-axis represents survival probability (%) and the x-axis represents time up to 57 months. The graph includes data on patients at risk for both treatment groups at various time points.*

FDA Label Image

Fulvestrant-fig-13 (Fulvestrant Fig 13)

A Kaplan-Meier survival curve chart showing event-free probability percentage over time (months) comparing two patient groups receiving Fulvestrant injection combined with either Ribociclib or placebo. The chart includes censoring times and a table of patient numbers at risk across 26 months.*

FDA Label Image

Fulvestrant-fig-14 (Fulvestrant Fig 14)

A line graph comparing event-free probability (%) over time (months) for two patient groups receiving Fulvestrant in combination with Ribociclib or Placebo. The x-axis represents time up to 48 months, and the y-axis shows event-free probability from 0% to 100%. Censoring times are indicated with markers, and patient numbers at risk are listed below the x-axis.*

FDA Label Image

Fulvestrant-fig-2 (Fulvestrant Fig 2)

An instructional diagram showing a hand holding a syringe with a needle cover being removed by pulling it upward. The right side of the image shows a detailed close-up of the syringe's needle attachment labeled with parts A, B, and C, illustrating the components involved in needle removal or attachment.*

FDA Label Image

Fulvestrant-fig-3 (Fulvestrant Fig 3)

An instructional illustration showing a pair of gloved hands preparing a syringe for injection. One hand holds the syringe barrel while the other hand adjusts the plunger. The image is likely related to the preparation of Fulvestrant 50 mg/mL injection for intramuscular administration.*

FDA Label Image

Fulvestrant-fig-4 (Fulvestrant Fig 4)

An instructional illustration showing a syringe connected to a vial, demonstrating the preparation or administration of an injection. The syringe is positioned horizontally and includes a plunger and needle attached to the vial.*

FDA Label Image

Fulvestrant-fig-5 (Fulvestrant Fig 5)

An instructional illustration showing a hand holding a vial with an arrow pointing upward, indicating how to hold or prepare the vial for use. The image relates to administration or preparation steps for Fulvestrant injection.*

FDA Label Image

Fulvestrant-fig-6 (Fulvestrant Fig 6)

A line graph titled 'Progression Free Survival (ITT Population)' displaying the proportion of patients progression free over time in months up to 45 months. Two curves compare Fulvestrant 250 mg and Fulvestrant 500 mg doses, with proportion values on the vertical axis and time on the horizontal axis. Below the graph, a table shows the number of patients at risk at various time points for both dosages.*

FDA Label Image

Fulvestrant-fig-7 (Fulvestrant Fig 7)

A survival curve chart displaying the proportion of patients alive over time (in months) for Fulvestrant at doses of 500 mg and 250 mg. The x-axis represents time in months up to 80, and the y-axis shows the proportion of patients alive from 0 to 1. The chart includes tick marks indicating censored observations and a table showing the number of patients at risk at various time points for both dosages.*

FDA Label Image

Fulvestrant-fig-8 (Fulvestrant Fig 8)

A Kaplan-Meier survival curve comparing progression-free survival (PFS) probabilities over time in months between two treatment groups: Fulvestrant 500 mg (solid line) and Anastrozole 1 mg (dashed line). The x-axis shows time from randomization, and the y-axis shows the probability of PFS. Below the graph is a table indicating the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Fulvestrant-fig-9 (Fulvestrant Fig 9)

A Kaplan-Meier curve showing progression-free survival probability (%) over time in months for two groups: Fulvestrant with palbociclib (solid line) and Fulvestrant with placebo (dashed line). The graph includes numbers of patients at risk at various time points for each group, illustrating comparative survival trends over approximately 14 months.*

FDA Label Image

Fulvestrant-pfs-label (Fulvestrant Pfs Label)

Label for Fulvestrant Injection 250 mg/5 mL (50 mg/mL) intramuscular injection by Alembic Pharmaceuticals Inc. The label includes the NDC 62332-650-05, dosage instructions, and storage precautions. It states that two single-dose prefilled syringes are required to administer the 500 mg dose. The product is manufactured in India and indicates protection from light is necessary.*

FDA Label Image

Fulvestrant-structure (Fulvestrant Structure)

Chemical structure of fulvestrant showing its molecular framework including hydroxyl groups and a sulfonyl-containing side chain with trifluoromethyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.